Use of Opioid Antagonists for the Preparation of a Medicament in the Treatment of Retinal Degenerative Diseases
Retinal degenerative diseases affect the delicate layer of retina tissue that lines the inside back of the eye leading to gradual vision loss. The use of opioid anatgonists for the preparation of a medicament for the selective blocking of the body's opioid receptors sites is a method of treating this human suffering by daily administration to the patient of from about 0.5 to about 10 mg of drugs such as naltrexone, naloxone or nalmefene. They act primarily by normalizing derangements in the human complement system that may occur in the disease etiology. Therapeutical approach for macular degeneration and retinitis pigmentosa is primarily intended. Oral, parenteral uses as well as topical applications may all be considered. They may be administered in one or divided doses daily for the best receptor blocking activity, preferably in the evening hours. Low Dose Naltrexone suitable for oral administration is most preferred regimen at about 4.5 mg/day.
1 - 12 . (canceled)
13 . A method for treating a retinal degenerative disease comprising administering to a patient in need thereof an effective amount of an opioid antagonist or a pharmaceutically acceptable salt thereof.
14 . The method of claim 13 , wherein the opioid antagonist is naltrexone.
15 . The method of claim 13 , wherein the opioid antagonist is naloxone.
16 . The method of claim 13 , wherein the opioid antagonist is nalmefene.
17 . The method of claim 13 , wherein the retinal degenerative disease is macular degeneration, retinitis pigmentosa, diabetic retinopathy, uveitis, retinal detachment, or an eye cancer.
18 . The method of claim 17 , wherein the retinal degenerative disease is macular degeneration.
19 . The method of claim 18 , wherein the macular degeneration is age-related macular degeneration.
20 . The method of claim 17 , wherein the retinal degenerative disease is retinitis pigmentosa.
21 . The method of claim 13 , wherein the opioid antagonist is administered to the patient orally, parenterally, or topically.
22 . The method of claim 13 , wherein the wherein the opioid antagonist is administered to the patient orally or parenterally.
23 . The method of claim 22 , wherein the opioid antagonist is administered to the patient in an amount of 0.5 mg to 10 mg per day.
24 . The method of claim 22 , wherein the opioid antagonist is administered to the patient in an amount of 0.5 mg to 5 mg per day.
25 . The method of claim 22 , wherein the opioid antagonist is administered to the patient in an amount of 4.5 mg per day.
26 . The method of claim 13 , wherein the opioid antagonist is administered to the patient topically.
27 . The method of claim 26 , wherein the opioid antagonist is administered to the patient in the form of a pharmaceutical composition comprising the opioid antagonist in an amount of 0.5% to 10% by weight of the composition.
28 . The method of claim 26 , wherein the opioid antagonist is administered to the patient in the form of a pharmaceutical composition comprising the opioid antagonist in an amount of 1% by weight of the composition.
29 . The method of claim 13 , wherein the opioid antagonist is administered to the patient once per day.
30 . The method of claim 13 , wherein the opioid antagonist is administered to the patient in divided doses per day.
31 . The method of claim 13 , wherein the opioid antagonist is administered to the patient in the form of a pharmaceutical composition comprising the opioid antagonist and at least one physiologically acceptable carrier.
32 . The method of claim 31 , wherein the pharmaceutical composition is in the form of a tablet, granule, dragee, capsule, sachet, cachet, caplet, lozenge, liposome, powder, solution, emulsion, liquid, syrup, cream, ointment, gel, eye drop, lotion, suppository, or enema.
33 . The method of claim 13 , further comprising administering an additional pharmacologically effective substance.